Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Day One Biopharmaceuticals Inc’s stock clocked out at $14.85, down -5.05% from its previous closing price of $15.64. In other words, the price has decreased by -$5.05 from its previous closing price. On the day, 1.03 million shares were traded. DAWN stock price reached its highest trading level at $15.915 during the session, while it also had its lowest trading level at $14.84.
Ratios:
To gain a deeper understanding of DAWN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 14.55 and its Current Ratio is at 14.62. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Needham on October 09, 2024, Reiterated its Buy rating but revised its target price to $33 from $32 previously.
On August 01, 2024, BofA Securities Upgraded its rating to Buy which previously was Underperform and also upped its target price recommendation from $11 to $24.
Needham reiterated its Buy rating for the stock on April 24, 2024, while the target price for the stock was revised from $30 to $33.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 08 ’24 when Blackman Samuel C. sold 18,255 shares for $16.17 per share. The transaction valued at 295,229 led to the insider holds 1,067,535 shares of the business.
Blackman Samuel C. sold 10,000 shares of DAWN for $160,994 on Nov 11 ’24. The HEAD OF R&D now owns 1,057,535 shares after completing the transaction at $16.10 per share. On Nov 11 ’24, another insider, SAMUEL BLACKMAN, who serves as the Officer of the company, bought 50,000 shares for $16.39 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DAWN now has a Market Capitalization of 1577233408 and an Enterprise Value of 941799488. For the stock, the TTM Price-to-Sale (P/S) ratio is 14.69 while its Price-to-Book (P/B) ratio in mrq is 2.70. Its current Enterprise Value per Revenue stands at 9.238 whereas that against EBITDA is -4.583.
Stock Price History:
Over the past 52 weeks, DAWN has reached a high of $18.07, while it has fallen to a 52-week low of $10.90. The 50-Day Moving Average of the stock is 2.80%, while the 200-Day Moving Average is calculated to be 1.24%.
Shares Statistics:
It appears that DAWN traded 1.03M shares on average per day over the past three months and 1687400 shares per day over the past ten days. A total of 87.23M shares are outstanding, with a floating share count of 68.17M. Insiders hold about 32.40% of the company’s shares, while institutions hold 65.61% stake in the company. Shares short for DAWN as of 1730332800 were 18018911 with a Short Ratio of 17.54, compared to 1727654400 on 15667396. Therefore, it implies a Short% of Shares Outstanding of 18018911 and a Short% of Float of 21.59.
